B
uprenorphine-naloxone is the most commonly prescribed buprenorphine formulation, a partial opioid agonist used for long-term management of opioid use disorder. 1 As part of a comprehensive treatment program, buprenorphine-naloxone is efficacious in reducing symptoms of opioid withdrawal and improving abstinence. 1, 2 Many patients value the convenience of receiving treatment on a prescription basis as compared with methadone maintenance, which typically is more managed than buprenorphine maintenance. 3 Patients generally experience better long-term outcomes when retained in treatment for longer periods of time and with greater continuity. 4 Guidelines support buprenorphine-naloxone treatment that is time unlimited, 5 but some insurers limit treatment duration and some individuals desire to use buprenorphine-naloxone for relatively short periods of time. Although buprenorphine is effective at both lower and higher dosages, studies indicate that patients often experience better abstinence with higher dosages (> 16 mg/d). 6 Research on buprenorphine treatment duration, dosage, and continuity (ie, adherence) has primarily been derived from clinical trials 7, 8 and observational studies of select populations, 9-13 such as single payers or practices, but less is known about differences in populations representative of individuals receiving care in the community. [14] [15] [16] Moreover, existing research focuses primarily on the first year; less is known about predictors of treatment lasting longer than 12 months. 17 Treatment patterns in community samples are important to study in light of concerns about the quality of care many patients receive and the capacity of office-based providers to effectively manage opioid use disorder. 18 Duration, dosage, and continuity in a community sample could be influenced by a variety of factors. Patient demographics such as age and sex may influence these outcomes, but have shown inconsistent relationships in published studies. 10, 12, 13 Treatment outcomes may be further associated with the policies of insurers such as dosage restrictions, prior authorization, and copayments common for buprenorphine-naloxone medication. 19 Clinic-level factors, including the specialty of the prescribing physician, could influence treatment outcomes insofar as some physicians may have greater capacity and expertise to manage longterm maintenance treatment. 20 Finally, area-level variables, which influence initiation and access to treatment, may also influence treatment outcomes. 9, 21 For example, patients who travel longer distances to visit their prescribing physician may experience greater barriers maintaining long-term treatment continuity. 22 We examined predictors of buprenorphine-naloxone treatment continuity, dosage, and duration, drawing upon a large, diverse database of individuals receiving treatment from prescribers in 11 states. Our sample includes treatment through all potential sources of payment, including cash, providing a more detailed and diverse picture of buprenorphine-naloxone treatment than studies from a single payer. This issue is particularly important because even patients with some public or private insurance may self-pay for some of their prescriptions of buprenorphine-naloxone. 23, 24 We hypothesized that both duration and continuity of care would be higher for individuals living in areas where travel distance was likely to be less to treatment, and in areas with relatively higher availability of providers and higher socioeconomic status. We also hypothesized that retention and dosage would be highest among individuals who had their care predominantly paid for by private insurance, as insurance may pay for a greater dosage or quantity of treatment than would otherwise be available.
DATA AND METHODS

Prescription Data
We used the QuintilesIMS Real World Data Anonymized Longitudinal Prescription database, which captures >75% of all prescriptions dispensed in the United States and are automatically reported to QuintilesIMS through weekly feeds from retail, foodstore, independent, and mass merchandiser pharmacies (some large networks do not participate in the database). QuintilesIMS then links data using a patented algorithm based on 16 different patient-level characteristics including name, address, date of birth, and sex. These anonymized, individual-level all-payer claims data contain detailed information for each prescription, including the fill date, dosage, days supply, and payment type.
Subjects
Our study was based on a larger cohort derived by identifying any patient filling 2 or more prescriptions for any opioid during any calendar year between 2006 and 2013 in 11 states (Arizona, California, Florida, Georgia, Louisiana, Maryland, New York, Oregon, Pennsylvania, Texas, Washington). We then extracted the universe of prescriptions for any sampled individual. Our study period ranged from January 1, 2009 through August 31, 2013. We focused on individuals initiating buprenorphine-naloxone between January 1, 2010 and July 31, 2012, thus using a 12-month "washout period" to ensure that incident use was captured while allowing for at least 13 months of follow-up. We limited our analysis to patients filling 100% of their claims at retail pharmacies that consistently reported data to QuintilesIMS during the study period. In our main analyses, we excluded the 27% of individuals exclusively using other buprenorphine formulations (eg, buprenorphine monotherapy), as this is generally reserved for use in select populations such as pregnant women. 25 In sensitivity analysis we found that these individuals were predominantly older and female, and had much shorter treatment episodes, however, including these individuals in our analyses yielded substantively similar results and conclusions. To capture the universe of patients' prescription fill activity, we limited our sample to patients who filled 100% of their prescriptions from pharmacies that consistently reported data to QuintilesIMS throughout the study period. We also limited our analysis to individuals age 18 years and above at the time of their index prescription fill and those who had evidence of prescription activity for any product during both the first and last 6 months of the study period. Our final sample included 27,273 individuals.
First Treatment Episode
We defined each patient's first buprenorphine-naloxone treatment episode as the date of the index fill until the first day of a gap where the patient had no buprenorphine-naloxone on-hand for 90 or more days. In many cases patients had overlapping buprenorphine-naloxone prescriptions as a result of early refills. We chose not to extend the length of the treatment episode for these patients because it was unclear if such overlapping prescription truly represented "stockpiling." We removed 7% of buprenorphine-naloxone claims with values above the 99th percentile of quantity dispensed (120 pills) or days supply (30 d) .
Similar to other investigations, 12, 17 we measured treatment retention by creating a binary measure of treatment episodes 180 days or longer (6-mo retention). Six months was chosen to facilitate comparison with other studies; findings are comparable when considering alternative cutoffs (3 and 9 mo; Appendix, Supplementary Digital Content 1, http://links.lww.com/MLR/B368). We also quantified total length of the first episode in days. We measured treatment continuity using the medication possession ratio, which reflects percent of days in which the individual had buprenorphine-naloxone available for use. We created a binary indicator reflecting individuals with a possession ratio of <80%. 26 We measured mean dosage in milligrams per day by calculating the daily dose per day and dividing by the number of days with prescribed medication. Finally, we created a binary indicator for the presence of any treatment interruptions, defined as a gap in the treatment episode of between 14 and 90 days when an individual had no buprenorphine-naloxone available for use and did not fill a prescription; as noted, after 90 days of no fills the episode was defined as terminated. We only calculated lowpossession ratio and treatment interruptions for individuals with 3 or more prescriptions, as these measures required multiple fills to calculate.
Patient, Physician, and Area-level Covariates
We examined the association between each outcome and several patient, physician, and area-level characteristics. We included patient age and sex. We also included an indicator for the patient's source of payment: third-party payment (a category which includes private insurance plans as well as Medicaid managed care plans), Medicare part D, Medicaid fee-for-service, and self-payment. For the 22% of the sample with multiple sources of payment, we imputed the most common source of payment. We examined the specialty type of physicians prescribing buprenorphine-naloxone: primary care physician (PCP) (general, internal, or family medicine), psychiatry, or some other specialty, and the county for the physician's office location. For the 24% of patients visiting multiple physicians, we imputed the most commonly visited physician.
Although we lacked a direct measure of patient's home address, we used the county of the pharmacy where the first prescription was filled as a proxy. Using the 2015 County Health Rankings, we included the percent of uninsured adults, the median household income, percent of the population that is non-Hispanic white (ie, nonminority), and the per capita rate of opioid overdose deaths in the year the individual began treatment (additional source information is available in the Appendix, Supplementary Digital Content 1, http://links.lww. com/MLR/B368). Overdose death data are reported in categories representing rates per 100,000 individuals, which we split into 4 approximately equal size groups (r10, 10.1-14, 14.1-17.9, Z18). Other county-level measures were mean standardized to facilitate interpretability. We included a 4-level measure of urbanicity of the county using definitions of metropolitan statistical areas (MSAs): large MSA ( > 1 million people), medium MSA ( > 250,000-1 million people), small MSA (100,000-250,000 people) and non-MSA (ie, rural).
Using the Drug Enforcement Administration 2015 directory of physicians with a waiver to prescribe buprenorphine for opioid use disorders, we created a per capita measure by dividing the number of waivered prescribing physicians by the county populations. Finally, comparing the location of the prescribing physician's county and the location of the pharmacy, we created an indicator for "out-ofcounty" treatment, reflecting claims where the physician was in a different county than the pharmacy.
Analyses
We examined 5 outcomes: (1) 6-month retention; (2) episode length in days; (3) mean dosage in milligrams per day; (4) low-possession ratio; and (5) treatment interruptions. We modeled each outcome in a separate regression model, using the complete set of patient-level, physician, and arealevel covariates. We fit models to an appropriate functional form for each outcome: logistic regression was used for the binary measures of 6-month retention, low-possession ratio, and treatment interruption. In addition to deriving odds ratios for these models, we also calculated regression-adjusted means for each covariate, calculating the predicted mean of the outcome at each covariate holding all other variables constant. We calculated ordinary least squares regression models for mean daily dosage.
We used an accelerated failure time model to calculate predictors of treatment length. This parametric model estimates time ratios (constant terms representing the amount by which each covariate accelerates/decelerates time on study). We clustered SE at the county-level corresponding to first pharmacy fill.
We tested for the goodness of fit of logistic regression models with Hosmer-Lemeshow statistics. To test for multicollinearity, we calculated variance inflation factors verifying that the variance inflation factor for each covariate was <10.
RESULTS
Sample Characteristics
About half the sample (48%) was female and half (50%) were age 18-34 (Table 1) . Most had third-party insurance as their main payment source (59.8%), followed by self-payment (25.9%), fee-for-service Medicaid (7.9%), and 
Retention at 6 Months
Overall, 41.4% of individuals were retained at 6 months ( Table 2) . After adjusting for all other covariates, individuals with treatment paid for by Medicaid fee-forservice and Medicare part D had very low adjusted means for 6-month retention: 22.3% and 21.1%, respectively (Table 3) . Individuals with health insurance paying for the majority of their treatment had significantly lower 
Episode Length
The mean treatment length was 266 days and the median was 118 days (Table 2) . Time ratios for length of treatment were similar to OR of retention at 6 months (Table 3) Figure 1 illustrates these dramatic differences in episode discontinuation using plots of the regression-adjusted survival rates by primary payer source from the model displayed in Table 3 .
Compared with individuals visiting PCPs, individuals visiting psychiatrists did not have statistically different time ratios. Those visiting specialists other than psychiatrists had lower ratios (0.82; 95% CI, 0.77-0.87). There were substantial differences in time ratios across states that followed similar patterns as 6-month retention.
Mean Daily Dosage
The mean daily dosage in the sample was 14.1 mg/d (Table 2) . After adjusting for all other covariates, the mean dosage was significantly higher among individuals with any form of insurance than with cash payment, with the mean daily dosage 1.37 mg/d higher among those in Medicaid feefor-service (95% CI, 0.96-1.78) and 1.14 mg/d higher among Medicare part D (95% CI, 0.77-1.51; Table 4 ). Individuals visiting psychiatrists had mean daily dosage that was À 0.8 mg/d lower than those visiting PCPs (95% CI, À 1.17 to À 0.38). The county-level variables had only a modest association with mean daily dosage. After adjusting for all covariates, there was notable variation across states in mean daily dosage-mean daily dosage was below 13 mg/d in Arizona and California, but was 14.8 mg/d in Pennsylvania and 15.1 mg/d in Louisiana.
Treatment Continuity
About 30.2% of treatment episodes with Z3 fills were associated with low-possession ratios ( Table 2 ). Odds of lowpossession ratio were relatively similar across groups by demographics, payment type, prescribing physician, and county. Adjusted rates of low-possession ratio ranged from about one quarter to one third of all individuals with significantly lower rates among individuals older than 50 (27.4%) and those residing in counties with more nonminority individuals (26.9%). Adjusted low-possession rates were highest in Florida (35.1%) and lowest in New Jersey (22.7%).
Treatment interruptions of 14-90 days were experienced by 25.5% of individuals with Z3 fills ( Table 2) . As with low possession, rates were relatively similar across demographic groups (Table 5) 
DISCUSSION
We evaluated patterns of buprenorphine-naloxone treatment in a multistate community sample using an allpayer dataset that includes self-paying patients and a longer time window than has previously been considered. Consistent with previously published estimates, 12, 17 we found that 41% of patients were retained in treatment for 6 months or longer. The mean length of treatment was 266 days and the median was 118 days. The longer mean length reflects some individuals remaining in treatment for multiple years. Each line represents the regression-adjusted survival curve for individuals with Medicare part D, Medicaid fee-for-service, third-party commercial insurance, or cash payment as their primary source of payment. Models adjust for age, sex, prescriber type, county level variables (county urbanicity, an indicator for crossing county lines for treatment, the primary care physician population ratio, the buprenorphine prescriber to population ratio, median income, nonminority population ratio, and county overdose death rate), and state fixed effects. RWD indicates Real World Data.
Our estimates of 6-month retention, 12 mean treatment length, 27 and adherence 27 are fairly consistent with data from studies conducted on more select populations. We also found that mean daily dosage was around 14 mg/d-a dosage generally considered to be in the "medium" range (7-15 mg/d) in clinical studies. 6 Individuals who predominantly paid for treatment with cash had longer treatment than those who paid with any form of insurance. This is surprising because cash paying patients are often uninsured and financially burdened to pay for treatment, factors that we hypothesized would lower retention. Several factors may explain this counterintuitive finding. First, many physicians who prescribe buprenorphine-naloxone do not accept health insurance. 24 There may be differences in the physicians who treat insured patients, or in the constraints at the practice-level, that could lead to low retention rates. Second, some insurance programs restrict length of treatment, covering buprenorphinenaloxone exclusively for detoxification or imposing a cap on the maximum days covered. 28, 29 In 2013, several state Medicaid programs imposed lifetime limits on buprenorphine treatment. 30 Third, for some patients, cash-payment may be a means of obtaining buprenorphine outside of insurance to divert for resale in the illicit market, as buprenorphine-naloxone has a high street value. Patients "opioid-shopping" for nonbuprenorphine opioids are more likely to pay cash, 31 but to our knowledge this relationship has not been established for buprenorphine-naloxone.
Other notable differences in retention occurred across states, with northeastern states (New York, New Jersey, and Maryland) having among the highest retention in the sample and Arizona and Florida having the lowest retention. Almost half of all patients crossed county lines for treatment, which may reflect geographic disparities in the location of waivered physicians. 32 However, county-level variables such as physician supply, median income, and the opioid overdose death rate had relatively small associations with retention.
Almost one third of patients had episodes with lowpossession ratios. Age was a marker of higher possession ratio, which may indicate that middle-aged and older individuals have differences in motivation or in socioeconomic barriers that increase their treatment adherence. However, the influence of most characteristics on possession ratio was relatively small, potentially indicating that efforts to improve adherence for buprenorphine-naloxone will need to be broadly targeted. Our study is subject to limitations. First, our database did not include patient diagnoses; we therefore are unable to adjust for comorbidities. This also means we cannot exclude patients being treated off-label for chronic pain 33 (who account for 11% of all buprenorphine prescriptions 34 ). Second, we lacked nonprescription service use, which could provide additional insight into quality of buprenorphine treatment, such as counseling visits with treatment, or outcomes that could be affected by treatment, such as hospitalizations for overdose. We lacked markers of clinical progress, illicit substance use, and relapse, and cannot determine if individuals with shorter treatment duration had worse clinical outcomes. Such information, even if obtained from a select subsample, could provide new insights into issues related to quality and patient health. Third, we could not measure how patients use medications prescribed to them. As mentioned, patients may divert medications prescribed to them for sale to other individuals. Diversion is a problem of growing importance requiring greater oversight in treatment programs. 35 Fourth, although we considered county-level characteristics, we could not identify sociodemographic characteristics of the sample such as patient's insurance status or individuallevel income. For example, measuring how much of the cash payment sample is truly uninsured could provide better insights into the motivation and resources of cash paying patients. Among those with third-party payment, we could not separately identify the subgroup with private insurance (a group accounting for 39% of all individuals treated for opioid use disorder). 36 Finally, county covariates such as the overdose death rate were measured after the study period, potentially introducing measurement error.
CONCLUSIONS
Low treatment retention for opioid use disorder is common across a variety of subgroups, and may be addressed through policy intervention. The surprising finding that individuals with insurance have lower retention compared with self-paying patients requires further investigation, and may underscore some issues with current coverage policies in both public and private insurance programs that restrict treatment length. State policies may also be important given the wide variation observed across states not attributable to differences in the county-level measures. These could include state-level differences in health care resources, the severity of the opioid epidemic, or to state funding for treatment programs for opioid use disorder. Identifying potential policies that may narrow these state differences is an important goal for research.
